# HERBY

Source: https://onco.cc/trials/herby/  
OnCo record `herby` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

HERBY asked whether adding the anti-blood-vessel antibody bevacizumab to radiotherapy and temozolomide would help children with high-grade brain tumours; it did not delay the tumours returning, so the drug is not part of standard treatment for these children.

## Summary

HERBY was an open-label randomised phase 2 trial in children and adolescents with newly diagnosed high-grade glioma outside the brainstem. After surgery, patients received radiotherapy with concurrent and adjuvant temozolomide, with or without bevacizumab.

Adding bevacizumab did not improve event-free survival, the primary endpoint, as judged by central review, and did not improve overall survival. The trial did produce one of the best-characterised molecular cohorts of paediatric high-grade glioma; its biology sub-study showed that histone H3 and IDH mutation status, rather than histology, separated the outcomes, which fed into the WHO classification of these tumours.

## Fields

- Kind: Trial
- Status: negative
- Last checked: 2026-09-17
- Tags: subtype-trials
- Registry id: NCT01390948
- Phase: 2
- Setting: Newly diagnosed non-brainstem high-grade glioma in children and adolescents aged 3 to 18: radiotherapy with temozolomide, with or without bevacizumab
- Sponsor: Roche
- Enrolled: 124
- Result: Bevacizumab added to radiotherapy and temozolomide did not improve event-free survival in newly diagnosed paediatric high-grade glioma.
- Outcomes: Event-free survival (central radiology review): Bevacizumab + radiotherapy + temozolomide 8.2 months vs Radiotherapy + temozolomide 11.8 months, HR 1.44; Overall survival: Bevacizumab + radiotherapy + temozolomide vs Radiotherapy + temozolomide, HR 1.23; Serious adverse events: Bevacizumab + radiotherapy + temozolomide 58% vs Radiotherapy + temozolomide 48%

## Sources

- ClinicalTrials.gov NCT01390948: https://clinicaltrials.gov/study/NCT01390948

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Paediatric high-grade glioma (excluding diffuse midline glioma)](https://onco.cc/cancers/paediatric-high-grade-glioma/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Temozolomide](https://onco.cc/drugs/temozolomide/)
- companies: [Roche / Genentech](https://onco.cc/companies/roche-genentech/)
- people: [Jacques Grill](https://onco.cc/people/jacques-grill/)

---
JSON: https://onco.cc/api/v1/entities/herby.json